



NEWS RELEASE

ANTARES PHARMA TO PRESENT AT THE COWEN AND COMPANY 35TH ANNUAL HEALTHCARE CONFERENCE

EWING, NJ, February 23, 2015 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present at the Cowen and Company 35th Annual Healthcare Conference on Monday March 2, 2015 at 2:50 pm Eastern Time.

A live webcast of the presentation will be available via the "Investor Information/Webcasts" page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares' website for 90 days following the presentation.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company markets OTREXUP[™] (methotrexate) injection for subcutaneous use in the treatment of adults with severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. LEO Pharma markets OTREXUP[™] to dermatologists for adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot[®] Testosterone for testosterone replacement therapy, and VIBEX[®] Sumatriptan for the acute treatment of migraines. The Company's technology platforms include VIBEX[®] disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd. that includes VIBEX[®] epinephrine, exenatide multi-dose pen, and another undisclosed multi-dose pen. Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring Pharmaceuticals BV.

Contact:

Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com